AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06340451 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iovera° system treatment
Description: subjects will receive ultrasound-guided iovera° sham system treatment
Study NCT04673305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment, Cytokine dosage
Description: Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
Study NCT05709145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written recommendation
Description: Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself.
Study NCT05357469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate St (Scrambler Therapy)
Description: Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
Study NCT05357469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waitlist ST (Scrambler Therapy)
Description: Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
Study NCT06227585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVEAL 475 System
Description: The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.
Study NCT06227585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
Study NCT05134454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extended ECG investigation
Description: At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
Study NCT06205160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOFT ECoG subdural grid electrode
Description: Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making.
Study NCT05203731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
Study NCT05203731 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sitting
Description: Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
Study NCT06218667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
Study NCT06218667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
Study NCT06218667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Standard treatment
Study NCT06532708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5x Oxycodone Oral Tablets
Description: Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.
Study NCT06532708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 16x Oxycodone Oral Tablets
Description: Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
Study NCT06592248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coc Knee
Description: Implementation of a ceramic on ceramic knee prosthesis
Study NCT06658912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TOPS Classes
Description: Attend Dietician-Led Sessions
Study NCT05371132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05371132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05614843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy density photobiomodulation (7.5)
Description: A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
Study NCT05614843 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham placebo
Description: A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
Study NCT05229848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D electroanatomical mapping alone guided CTI ablation
Description: 3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
Study NCT05229848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICE plus 3D electroanatomical mapping guided CTI ablation
Description: ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
Study NCT05618054 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Looming task
Description: Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
Study NCT05371132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89-Df-Crefmirlimab
Description: Given IV
Study NCT04960475 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxious and Depression(HADS)
Description: The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
Study NCT04960475 — intervention group
Intervention type: OTHER
Intervention: Fear-Avoidance Belief Questionnaire (FABQ)
Description: FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
Study NCT05371132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT for Lymphoma patients only
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:IV Infusion
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:SC Injection
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riliprubart
Description: Pharmaceutical form:Solution-Route of administration:SC Injection
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:SC Injection
Study NCT06290128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:SC Injection
Study NCT05867927 — intervention group
Intervention type: DEVICE
Intervention: Robotic-assisted surgery (da Vinci)
Description: Robotic-assisted surgery (da Vinci)
Study NCT05867927 — intervention group
Intervention type: DEVICE
Intervention: Non-da Vinci Surgery
Description: Non-da Vinci Surgery
Study NCT06670326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting
Description: Experimental: Baseline-Preparation-Imagery Rescripting-Post Treatment Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The treatment for PAD will be based upon the protocol described by Arntz \& Weertman (1999); (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
Study NCT06670612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature based music concert
Description: It will be a resource for healthcare professionals to develop a behavior that will support patients in intensive care in relieving their pain and stabilizing their physiological parameters with nature-based music, and will contribute to the literature.
Study NCT06670443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
Study NCT06670443 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
Study NCT06668935 — intervention group
Intervention type: DEVICE
Intervention: To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
Description: All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
Study NCT06669299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-Do ventricular tachycardia ablation
Description: 1. Programmed ventricular stimulation (PVS); 2. Mapping during Sinus Rhythm (SR) or right ventricular pacing in pacing dependent patients; 3. Late Potentials identification; 4. VT(s) induction with diastolic pathway mapping when possible; 5. Catheter Ablation in SR or, at the operator's discretion, in VT if tolerated by the patient; 6. If VT is not inducible or the diastolic pathway is not mappable, a substrate ablation approach will be performed. 7. PVS is repeatedly attempting to reinduce VT after completing; 8. Endpoint: non-inducibility of any VT.
Study NCT06669299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)
Description: The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
Study NCT05868629 — intervention group
Intervention type: OTHER
Intervention: Non-investigational
Description: Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
Study NCT06595108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
Study NCT04707768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral tablets
Study NCT04707768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mircera®
Description: intravenous administration
Study NCT06669403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT101
Description: OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
Study NCT06669403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
Study NCT06669728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI diagnostic algorithm
Description: The ICL procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
Study NCT05669378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite to Play +
Description: In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
Study NCT05669378 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Appetite to Play +
Description: In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
Study NCT05442515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR-transduced T cells
Description: CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
Study NCT05442515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
Study NCT05962333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-arterial delivery of autologous MABs
Description: three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval
Study NCT05442515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
Study NCT04724928 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Metastasis directed therapy (MDT)
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
Study NCT04724928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
Study NCT04724928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
Study NCT06156410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
Study NCT04452500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT108297
Description: CORT108297- 180mg daily for 7 days
Study NCT04452500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- 180mg daily for 7 days
Study NCT05296122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.
Description: The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
Study NCT05561114 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GIE Medical ProTractX3 TTS DCB
Description: Paclitaxel Coated Balloon
Study NCT05561114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Endoscopic Dilation
Study NCT06681870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1893
Description: Intravenous infusion
Study NCT04809363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDPATH™
Description: Crohn's disease risk prediction tool.
Study NCT04809363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Three blood samples will be drawn.